Osiris Therapeutics (OSIR) 5.01 $OSIR Osiris Provides

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:01 AM

Osiris Therapeutics (OSIR) 5.01 $OSIR

Osiris Provides Update Regarding NASDAQ Listing Matters
GlobeNewswire - Wed Aug 17, 4:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"

today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ"

.
OSIR: 5.01 (unch)

Osiris Therapeutics, Inc. (Nasdaq: OSIR) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Aug 05, 9:00AM CDT
What:
OSIR: 5.01 (unch), NDAQ: 71.24 (+0.03)

Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal
GlobeNewswire - Thu Aug 04, 3:33PM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal, is now available online and will appear in an upcoming issue of the journal.
OSIR: 5.01 (unch)

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Osiris Therapeutics, Inc. and Advises Investors to Contact the Firm
BusinessWire - Thu Jun 02, 11:49AM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(Nasdaq: OSIR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
OSIR: 5.01 (unch)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Osiris Therapeutics, Inc. -- OSIR
BusinessWire - Wed Jun 01, 10:08AM CDT
Levi & Korsinsky announces it has commenced an investigation of Osiris Therapeutics, Inc. ("Osiris Therapeutics" or the "Company"

(NASDAQ: OSIR) concerning possible violations of federal securities laws.
OSIR: 5.01 (unch), MDXG: 7.08 (-0.16)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Osiris Therapeutics, Inc.
PR Newswire - Wed Jun 01, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NasdaqGM: OSIR -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at
OSIR: 5.01 (unch)

INVESTOR ALERT: Investigation of Osiris Therapeutics, Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Tue May 31, 1:28PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Osiris Therapeutics, Inc. ("Osiris" or the "Company"

(NASDAQ: OSIR) concerning the Company and its officers' possible violations of federal securities laws.
OSIR: 5.01 (unch)

MiMedx Files Lawsuit Against Osiris For False And Misleading Representations
PR Newswire - Tue May 17, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has filed a lawsuit under the Lanham Act against Osiris Therapeutics, Inc. for permanent injunctive relief and damages.
OSIR: 5.01 (unch), MDXG: 7.08 (-0.16)

Osiris to Present at the 26th European Wound Management Association Conference
BusinessWire - Tue May 10, 3:00PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the 26th European Wound Management Association Conference.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Grafix Demonstrates Superior Clinical Outcomes Compared with EpiFix in "Real World" Study
BusinessWire - Mon May 02, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announces the results of A Retrospective, Single-Center, Non-Randomized, Cross-Sectional Comparative Effectiveness Study Evaluating Surface Area Reduction, Volume Reduction and Closure Rates in Acute and Chronic Wounds Managed with Grafix(R) versus EpiFix(R).
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Osiris to Present 15 Advanced Clinical and Scientific Abstracts
BusinessWire - Tue Apr 12, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring Conference, the nation's largest interdisciplinary wound care event within the clinical field.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Osiris Announces Further Expansion of Grafix Commercial Coverage
BusinessWire - Fri Apr 08, 11:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that over 52 million commercial beneficiaries are covered for Grafix(R).
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Dipexium Progresses on Phase III Diabetic Foot Ulcer Studies
Zacks Equity Research - Zacks Investment Research - Fri Feb 05, 2:50PM CST
Dipexium (DPRX) attains 75% enrollment milestone in two phase III studies on Locilex for the treatment of patients with mild infections of diabetic foot ulcers.
DPRX: 12.58 (-0.12), OSIR: 5.01 (unch), LGND: 104.53 (+1.22), ANIK: 46.80 (-0.44)

Shares of OSIR Down 63.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 04, 3:37PM CST
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on October 6th, 2015 at $16.79. In approximately 4 months, Osiris Therapeutics has returned 63.06% as of today's recent price of $6.20.
OSIR: 5.01 (unch)

Why Shares of Osiris Therapeutics Tanked Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 04, 10:15AM CST
What : Shares of the regenerative-medicine company Osiris Therapeutics fell by as much as 16% in early trading Thursday on modest volume after the company announced a major shake-up in its leadership team. Specifically, Dwayne Montgomery is taking...
OSIR: 5.01 (unch)

Osiris Therapeutics Announces Leadership Transition
BusinessWire - Wed Feb 03, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Dwayne Montgomery, its current Chief Business Officer, has been appointed today to serve as Interim Chief Executive Officer. Frank Czworka, currently Vice President and General Manager of Wound Care, has been promoted to Chief Operating Officer. Mr. Montgomery will replace Dr. Lode Debrabandere who today has announced his resignation for personal reasons from Osiris.
OSIR: 5.01 (unch), SYK: 114.94 (-0.72)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...